Tirzepatide
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly · Phase 3 · Completed · Enrollment 441
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Tirzepatide 5 milligram (mg) | n/r | n/r | n/r | n/r |
| Tirzepatide Maximum Tolerated Dose | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Tirzepatide 5 milligram (mg): endpoint not reported
- Tirzepatide Maximum Tolerated Dose: endpoint not reported
- Placebo: endpoint not reported